Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 49 / Drugs : 73 - (DrugBank : 19) / Drug target genes : 14 - Drug target pathways : 134

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

100% oxygen
   Jay C. Buckey Jr.
      2026   Phase 4   NCT07240649   -
ABC008
   Abcuro, Inc.
      2024   Phase 2/Phase 3   NCT06450886   Australia;United States
      2023   Phase 2/Phase 3   NCT05721573   Australia;Belgium;Canada;France;Germany;United Kingdom;United States
      2021   Phase 1   NCT04659031   Australia
Adsvf
   Assistance Publique - Hôpitaux de Paris
      2023   Phase 1   NCT05032131   France
Alemtuzumab
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00079768   United States
Anakinra
   Karolinska Institutet
      2003   Phase 2/Phase 3   NCT01165008   Sweden
Anthropometry
   Manchester Metropolitan University
      2026   -   NCT07535996   United Kingdom
Arimoclomol
   Orphazyme
      2019   Phase 3   NCT04049097   United Kingdom;United States
      2017   Phase 2   NCT02753530   United Kingdom;United States
   Richard Barohn, MD
      2008   Phase 2/Phase 3   NCT00769860   United Kingdom;United States
   UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit
      2009   Phase 2   EUCTR2008-008208-42-GB   United Kingdom
Arimoclomol citrate
   Orphazyme A/S
      2019   Phase 3   EUCTR2019-000749-11-GB   United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-004903-33-GB   United Kingdom;United States
Behavioural monitoring
   Manchester Metropolitan University
      2026   -   NCT07535996   United Kingdom
Bimagrumab
   NOVARTIS FARMA S.P.A.
      2015   Phase 3   EUCTR2015-001411-12-IT   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-000705-23-IT   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
   Novartis Pharma K.K.
      2015   Phase 2-3   JPRN-jRCT2080223024   -
      2013   Phase 2-3   JPRN-jRCT2080222316   -
   Novartis Pharma Services AG
      2015   Phase 3   EUCTR2015-001411-12-NL   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-GB   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-FR   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-DK   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-BE   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
   Novartis Pharmaceuticals
      2015   Phase 3   NCT02573467   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2014   Phase 2/Phase 3   NCT02250443   United States
Blood collection
   Centre Hospitalier Universitaire de Nice
      2018   -   NCT03299335   France
Blood draw FOR optional genetic exome sequencing
   LMU Klinikum
      2022   -   NCT05272969   Germany
Blood-flow restricted training
   University of Southern Denmark
      2015   -   NCT02317094   Denmark
Borg scale
   LMU Klinikum
      2022   -   NCT05272969   Germany
Botulinum toxin type A
   Rigshospitalet
      2014   Phase 2   EUCTR2014-002210-23-DK   Denmark
BRX-345
   Orphazyme A/S
      2019   Phase 3   EUCTR2019-000749-11-GB   United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-004903-33-GB   United Kingdom;United States
   UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit
      2009   Phase 2   EUCTR2008-008208-42-GB   United Kingdom
BYM338
   NOVARTIS FARMA S.P.A.
      2015   Phase 3   EUCTR2015-001411-12-IT   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-000705-23-IT   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
   Novartis Pharma K.K.
      2015   Phase 2-3   JPRN-jRCT2080223024   -
      2013   Phase 2-3   JPRN-jRCT2080222316   -
   Novartis Pharma Services AG
      2015   Phase 3   EUCTR2015-001411-12-NL   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-GB   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-FR   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-DK   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2015-001411-12-BE   Australia;Belgium;Denmark;France;Italy;Japan;Netherlands;Switzerland;United Kingdom;United States
      2014   -   EUCTR2013-000705-23-NL   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-000705-23-GB   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-000705-23-DK   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-000705-23-DE   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
      2014   -   EUCTR2013-000705-23-BE   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
   Novartis Pharmaceuticals
      2014   Phase 2/Phase 3   NCT02250443   United States
      2011   Phase 2   NCT01423110   United States
BYM338/bimagrumab
   Novartis Pharmaceuticals
      2013   Phase 2/Phase 3   NCT01925209   Australia;Belgium;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Switzerland;United Kingdom;United States
Capillary blood sampling
   Manchester Metropolitan University
      2026   -   NCT07535996   United Kingdom
Care AS usual
   University of Southern Denmark
      2015   -   NCT02317094   Denmark
Dynamometry
   LMU Klinikum
      2022   -   NCT05272969   Germany
   Manchester Metropolitan University
      2026   -   NCT07535996   United Kingdom
Etanercept
   Washington University School of Medicine
      2005   Phase 0   NCT00802815   United States
Gamma globulin
   National Institute of Neurological Disorders and Stroke (NINDS)
      1990   Phase 2   NCT00001261   United States
Genetic test: ACE polymorphism
   LMU Klinikum
      2022   -   NCT05272969   Germany
Genetic test: ACTN3 polymorphism
   LMU Klinikum
      2022   -   NCT05272969   Germany
Hyperbaric oxygen
   Jay C. Buckey Jr.
      2026   Phase 4   NCT07240649   -
Indirect calorimetry
   Manchester Metropolitan University
      2026   -   NCT07535996   United Kingdom
Laboratory assessment: calcium
   LMU Klinikum
      2022   -   NCT05272969   Germany
Laboratory assessment: creatine kinase
   LMU Klinikum
      2022   -   NCT05272969   Germany
Laboratory assessment: magnesium
   LMU Klinikum
      2022   -   NCT05272969   Germany
Laboratory assessment: phosphate
   LMU Klinikum
      2022   -   NCT05272969   Germany
Laboratory assessment: vitamin D level
   LMU Klinikum
      2022   -   NCT05272969   Germany
Magnetic resonance imaging
   Manchester Metropolitan University
      2026   -   NCT07535996   United Kingdom
Muscle ultrasound
   LMU Klinikum
      2022   -   NCT05272969   Germany
Natalizumab
   Phoenix Neurological Associates, LTD
      2013   Phase 1   NCT02483845   United States
Phenylbutyrate oral tablet
   University of Kansas Medical Center
      2020   Phase 1   NCT04421677   United States
Pioglitazone
   Johns Hopkins University
      2018   Phase 1   NCT03440034   United States
Pozelimab/cemdisiran
   Austin Neuromuscular Center
      2024   Early Phase 1   NCT06479863   United States
Pressure pain threshold
   LMU Klinikum
      2022   -   NCT05272969   Germany
Quick motor function test
   LMU Klinikum
      2022   -   NCT05272969   Germany
RAAV1.CMV.hufollistatin344
   Nationwide Children's Hospital
      2012   Phase 1   NCT01519349   United States
Rapamycin
   Institut National de la Santé Et de la Recherche Médicale, France
      2015   Phase 2/Phase 3   NCT02481453   France
REGN2477+REGN1033
   Regeneron Pharmaceuticals
      2019   Phase 2   NCT03710941   -
Ruxolitinib
   Assistance Publique - Hôpitaux de Paris
      2025   Phase 2   NCT06536166   France
Simvastatin
   ISTITUTO NEUROLOGICO CARLO BESTA
      2007   -   EUCTR2007-004359-12-IT   Italy
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2007   -   EUCTR2006-005942-35-IT   Italy
Sirolimus
   University of Kansas Medical Center
      2022   Phase 3   NCT04789070   Australia;Netherlands;United States
Sivastin
   ISTITUTO NEUROLOGICO CARLO BESTA
      2007   -   EUCTR2007-004359-12-IT   Italy
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2007   -   EUCTR2006-005942-35-IT   Italy
Ulviprubart
   Abcuro, Inc.
      2024   Phase 2/Phase 3   NCT06450886   Australia;United States
Vital signs
   LMU Klinikum
      2022   -   NCT05272969   Germany
Whole-body DUAL-energy X-RAY absorptiometry
   Manchester Metropolitan University
      2026   -   NCT07535996   United Kingdom
Xeomin
   Rigshospitalet
      2014   Phase 2   EUCTR2014-002210-23-DK   Denmark